NCT05092529 (PIM-COVID) is a clinical trial in COVID-19, sponsored by Royal Liverpool University Hospital.

Who is sponsoring NCT05092529?

NCT05092529 is sponsored by Royal Liverpool University Hospital.

What condition does NCT05092529 study?

NCT05092529 studies COVID-19, Psychological Distress, Depression, Anxiety, Post-traumatic Stress Disorder, Post Intensive Care Syndrome.

Is NCT05092529 still recruiting?

NCT05092529 is currently completed. Last updated 28 November 2023.

Last reviewed 2023-11-28 · How we verify

NCT05092529: PIM-COVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psychological Impact of COVID-19 on Intensive Care Survivors

Completed Last updated 28 November 2023

What this trial tests

trial in COVID-19 in 1,620 participants. Completed in 17 November 2023.

Timeline

17 November 2020

Primary endpoint
14 February 2023

17 November 2023

Quick facts

Lead sponsor	Royal Liverpool University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,620
Start date	17 November 2020
Primary completion	14 February 2023
Estimated completion	17 November 2023
Sites	50 locations across United Kingdom

Conditions studied

COVID-19 — all drugs for COVID-19 →
Psychological Distress — all drugs for Psychological Distress →
Depression — all drugs for Depression →
Anxiety — all drugs for Anxiety →

Sponsor

Royal Liverpool University Hospital

Who can join

18 and older, any sex, with COVID-19 or Psychological Distress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Psychological distress is commonly experienced by survivors of an intensive care admission, including patients treated during previous pandemics. Whilst data emerges about the short-term impact of COVID-19 on patients and healthcare systems, the long term impact remains unclear. The purpose of this trainee-led, multi-centre longitudinal study is to assess the short- and long-term psychological impact on patients who have survived an admission to intensive care due to COVID-19, and identify possible predictors of anxiety, depression and trauma symptoms in this patient group.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Psychological impact of an intensive care admission for COVID-19 on patients in the United Kingdom.
Waite AA, Cherry MG, Brown SL, Williams K, et al · · 2025 · cited 3× · PMID 39801629 · DOI 10.1177/17511437241312113
PIM-COVID study: protocol for a multicentre, longitudinal study measuring the psychological impact of surviving an intensive care admission due to COVID-19 on patients in the UK.
Waite AAC, Johnston BW, Boyle AJ, Cherry MG, et al · · 2023 · cited 2× · PMID 37758678 · DOI 10.1136/bmjopen-2023-071730

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Royal Liverpool University Hospital trials

Trials by the same sponsor.

NCT01783106 — Antibiotics and Hydroxychloroquine in Crohn's · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05092529 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Royal Liverpool University Hospital
Last refreshed: 28 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05092529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing